LBA
GOSS icon

Letko, Brosseau & Associates’s Gossamer Bio GOSS Stock Holding History

Letko, Brosseau & Associates’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,400
Closed -$12.9K – 114
2026
Q1 		$12.9K Hold
39,400
– – ﹤0.01% 101
2025
Q4 		$122K Hold
39,400
– – ﹤0.01% 95
2025
Q3 		$104K Buy
+39,400
New +$86.8K ﹤0.01% 94

Other funds holding GOSS

D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Letko, Brosseau & Associates's GOSS Position: Q2 2026 in Review

Letko, Brosseau & Associates sold out of Gossamer Bio (GOSS) in Q2 2026, closing a stake of 39,400 shares — an estimated $12.9K sold.

Letko, Brosseau & Associates first reported a position in GOSS in Q3 2025 and held it in 3 quarters. The position peaked at $122K in Q4 2025. 170 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Letko, Brosseau & Associates reported no remaining Gossamer Bio position as of Q2 2026 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 39,400 Gossamer Bio shares in Q2 2026, an estimated $12.9K.
  • Letko, Brosseau & Associates first reported a position in Gossamer Bio in Q3 2025 and held it in 3 quarters.
  • Letko, Brosseau & Associates's Gossamer Bio position peaked at $122K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.